赫尔格
化学
喹唑啉
效力
逆转录酶
体外
药理学
体内
选择性
结构-活动关系
微粒体
脚手架
药品
立体化学
化学合成
生物化学
毒性
药物发现
铅化合物
代谢稳定性
组合化学
IC50型
酶抑制剂
逆转录酶抑制剂
钾通道
酶
生物活性
安全药理学
作者
Yujie Zhang,Qian Xu,Hao Deng,Limin Zhao,Xiaomei Chen,Ling Dong,Yu-Ting Niu,Zhen-Zhu Lei,Christophe C. Pannecouque,Erik De Clercq,Phuong‐Thao Tran,Xian-Kai Li,Peng Qi,Peng Liu,Lingbo Qu,Li Qiang Wan,Shuai Wang,Fen‐Er Chen
标识
DOI:10.1021/acs.jmedchem.6c02971
摘要
Abstract In this work, a series of tetrahydropyrido[3,4-d]pyrimidine derivatives were rationally designed as HIV-1 non-nucleoside reverse transcriptase inhibitors via scaffold modification. Most compounds demonstrated promising potency against wild-type HIV-1 (IIIB) and clinically relevant mutants. Notably, 10p showed the strongest activity against HIV-1 IIIB, L100I, K103N, Y188C, Y188L, and E138K (EC50 = 2.4−16.5 nM). Importantly, 10p maintained potent efficacy against F227L/V106A (EC50 = 12.3 nM) and K103N/Y181C (EC50 = 21.7 nM). In vitro assessment revealed that the metabolic clearance rate of 10p in human liver microsomes was moderately lower than that of rilpivirine. Additionally, 10p showed a low potential for CYP-mediated drug interactions and had a negligible inhibitory effect on the hERG potassium channel. In the acute oral toxicity study in mice, no adverse effects were observed at a dose of up to 2000 mg/kg. These findings identify 10p as a promising lead compound for further development.
科研通智能强力驱动
Strongly Powered by AbleSci AI